Convergences in Course of Illness and Treatments of the Epilepsies and Recurrent Affective Disorders

Clinical EEG and Neuroscience

Volumn 35, Issue 1, 2004, Pages 14-24

  Post, Robert M ^a   Weiss, Susan R b ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Affective Disorders; Amygdala Kindling; Anticonvulsants; Depression; Mania; Mood Stabilizers; Seizures; Tolerance

Indexed keywords

ANTICONVULSIVE AGENT; ATROPINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CLONAZEPAM; CLONIDINE; DIAZEPAM; DIZOCILPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; OXCARBAZEPINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZONISAMIDE;

AMYGDALOID NUCLEUS; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERANCE; EPILEPSY; HUMAN; KINDLING; MOOD DISORDER; NEUROBIOLOGY; PRIORITY JOURNAL; PSYCHOTHERAPY; RECURRENT DISEASE; REMISSION; REVIEW; SEIZURE;

AMYGDALA; ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; COMORBIDITY; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; EPILEPSY, COMPLEX PARTIAL; HUMANS; KINDLING, NEUROLOGIC; MOOD DISORDERS; RATS; RECURRENCE; TREATMENT OUTCOME;

EID: 1842481622     PISSN: 15500594     EISSN: None     Source Type: Journal    
DOI: 10.1177/155005940403500108     Document Type: Article

References (44)

1. Kwan P Brodie MJ. Refractory epilepsy: A progressive, intractable but preventable condition? Seizure 2002; 11: 77-84.
2. Maj M Pirozzi R Magliano L Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 30-35.
3. Denicoff KD Smith-Jackson EE Disney ER Ali SO Leverich GS Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-478.
4. Goldberg JF Harrow M Leon AC. Lithium treatment of bipolar affective disorders under naturalistic followup conditions. Psychopharmacol Bull 1996; 32: 47-54.
5. Gumnick JF Nemeroff CB. Problems with currently available antidepressants. J Clin Psychiatry 2000; 61 (suppl) 10: 5-15.
6. Kraepelin E. Manic-depressive insanity and paranoia. Edinburgh: E.S. Livingstone; 1921.
7. Kessing LV Andersen PK Mortensen PB Bolwig TG. Recurrence in affective disorder. I. Case register study. Br J Psychiatry 1998; 172: 23-28.
8. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149: 999-1010.
9. Kendler KS Thornton LM Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: An evaluation of the “kindling” hypothesis. Am J Psychiatry 2000; 157: 1243-1251.
10. Kendler KS Thornton LM Gardner CO. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry 2001; 158: 582-586.
11. Goddard GV McLntyre DC Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969; 25: 295-330.
12. Racine R. Kindling: The first decade. Neurosurgery 1978; 3: 234-252.
13. Weiss SR Post RM. Caveats in the use of the kindling model of affective disorders. Toxicol Ind Health 1994; 10: 421-447.
14. Reynolds EH. Early treatment and prognosis of epilepsy. Epilepsia 1987; 28: 97-106.
15. Post RM Denicoff KD Leverich GS Altshuler LL Frye MA Suppes TM, et al. Presentations of depression in bipolar illness. Clin Neurosci Res 2002; 2: 142-157.
16. Weiss SR Clark M Rosen JB Smith MA Post RM. Contingent tolerance to the anticonvulsant effects of carbamazepine: Relationship to loss of endogenous adaptive mechanisms. Brain Res Rev 1995; 20: 305-325.
17. Pazzaglia PJ Post RM. Contingent tolerance and reresponse to carbamazepine: A case study in a patient with trigeminal neuralgia and bipolar disorder. J Neuropsychiatry Clin Neurosci 1992; 4: 76-81.
18. Post RM Leverich GS Rosoff AS Altshuler LL. Carbamazepine prophylaxis in refractory affective disorders: A focus on long-term follow-up. J Clin Psychopharmacol 1990; 10: 318-327.
19. Krupp E Heynen T Li XL Post RM Weiss SR. Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: Cross-tolerance to carbamazepine but not valproate or diazepam. Exp Neurol 2000; 162: 278-289.
20. Weiss SR Post RM Sohn E Berger A Lewis R. Cross-tolerance between carbamazepine and valproate on amygdala-kindled seizures. Epilepsy Res 1993; 16: 37-44.
21. Clark M Massenburg GS Weiss SR Post RM. Analysis of the hippocampal GABAA receptor system in kindled rats by autoradiographic and in situ hybridization techniques: contingent tolerance to carbamazepine. Brain Res Mol Brain Res 1994; 26: 309-319.
22. Zhang ZJ Russell S Obeng K Postma T Obrocea G Weiss SR Post RM. Coadministration of gabapentin or MK-801 with lamotrigine slows tolerance to its anticonvulsant effects on kindled seizures. Pharmacol Biochem Behav 2003; 74: 565-571.
23. Post RM Weiss SR. Ziskind-Somerfeld Research Award 1992. Endogenous biochemical abnormalities in affective illness: Therapeutic versus pathogenic. Biol Psychiatry 1992; 32: 469-484.
24. Wan RQ Noguera EC Weiss SR. Anticonvulsant effects of intra-hippocampal injection of TRH in amygdala kindled rats. Neuro Report. 1998; 9: 677-682.
25. Pinel JPJ. Effects of diazepam and diphenylhydantoin on elicited and spontaneous seizures in kindled rats: A double dissociation. Pharmacol Biochem Behav 1983; 18: 61-63.
26. Iudice A Murri L. Pharmacological prophylaxis of post-traumatic epilepsy. Drugs 2000; 59: 1091-1099.
27. Altshuler LL Post RM Leverich GS Mikalauskas K Rosoff A Ackerman L. Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am J Psychiatry 1995; 152: 1130-1138.
28. Obrocea GV Dunn RM Frye MA Ketter TA Luckenbaugh DA Leverich GS, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002; 51: 253-260.
29. Pazzaglia PJ Post RM Ketter TA George MS Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 1993; 49: 257-272.
30. Pazzaglia PJ Post RM Ketter TA Callahan AM Marangell LB Frye MA, et al. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol 1998; 18: 404-413.
31. Kramlinger KG Post RM. Ultra-rapid and ultradian cycling in bipolar affective illness. Br J Psychiatry 1996; 168: 314-323.
32. Duman RS. Synaptic plasticity and mood disorders. Mol Psychiatry 2002; 7(suppl 1): S29-S34.
33. Nibuya M Morinobu S Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-7547.
34. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999; 40(suppl 5):S2-S10.
35. Post RM Berrettini WH Uhde TW Kellner CH. Selective response to the anticonvulsant carbamazepine in manic-depressive illness: A case study. J Clin Psychopharmacol 1984; 4: 178-185.
36. Post RM Altshuler LL Ketter TA Denicoff K Weiss SRB. Antiepileptic drugs in affective illness: Clinical and theoretical implications. In: Smith DB, Treiman DM, Trimble MR, (eds). Advances in Neurology: Neurobehavioral Problems in Epilepsy. New York: Raven Press; 1991; 55: 239-277.
37. Manji HK Lenox RH. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999; 46: 1328-1351.
38. Bebchuk JM Arfken CL Dolan-Manji S Murphy J Hasanat K Manji H.K. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000; 57: 95-97.
39. Passmore MJ Garnham J Duffy A MacDougall M Munro A Slaney C, et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar disord 2003; 5: 110-114.
40. Post RM Speer AM Weiss SR Li H. Seizure models: Anticonvulsant effects of ECT and rTMS. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 1251-1273.
41. George MS Sackeim HA Rush AJ Marangell LB Nahas Z Husain MM, et al. Vagus nerve stimulation: A new tool for brain research and therapy. Biol Psychiatry 2000; 47: 287-295.
42. Rush AJ George MS Sackeim HA Marangell LB Husain MM Giller C, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: A multicenter study. Biol Psychiatry 2000; 47: 276-286.
43. Marangell LB Rush AJ George MS Sackeim HA Johnson CR Husain MM, et al. Vagus nerve stimulation (VNS) for major depressive episodes: One year outcomes. Biol Psychiatry 2002; 51: 280-287.
44. Sackeim HA Rush AJ George MS Marangell LB Husain MM Nahas Z, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: Efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001; 25: 713-728.